Quince Therapeutics shares surge 28.99% premarket after settling $16.4M EIB debt for $5.5M, boosting strategic flexibility.

Quince Therapeutics surged 28.99% in premarket trading following the announcement that it successfully settled $16.4 million in outstanding debt obligations with the European Investment Bank for a $5.5 million payment. The resolution of this significant debt burden is a major milestone in the company’s restructuring efforts and removes a key overhang, enhancing its flexibility to pursue strategic alternatives such as mergers, asset sales, or other transactions aimed at maximizing shareholder value. The move is seen as a positive step forward for Quince as it continues its corporate evaluation process.